US Encouraging Monkeypox Vaccine Maker To Work With Large Pharma To Up Supply
The US FDA's Peter Marks also says the intradermal dose-sparing plan was motivated by concern over city and state one-dose strategies.
The US FDA's Peter Marks also says the intradermal dose-sparing plan was motivated by concern over city and state one-dose strategies.